Antibodies Derived From Dyax Corp. Library Enter Clinical Trials At ImClone Systems
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2005--Dyax Corp. (Nasdaq:DYAX) announced today that two fully human monoclonal antibodies that were derived from Dyax's proprietary phage display libraries have entered into Phase I clinical development at ImClone Systems, as recently reported by the Dyax library licensee.